Dr. Rafael Bejar
position treatment [Indiscernible] Bill. B-cell malignancies, and of of for kinase We're two for AML having fortunate oral the AML, both HMXXXXX the Thanks, inhibitors well-differentiated cancers. in for hematologic
talk First, XXX. about let's
inhibiting a candidate demonstrated highly that already other is wild XXX product type FLTX both remissions multiple and tested. of or inhibitor, has lead Our effective all FLTX complete forms CRs.
FLTX highlight be In oncogenic disrupt as targets, It to is FLTX gilteritinib combined an more XXX to among venetoclax fact, and resistance. also kinase demonstrated and that best a tested growth CKIT, language, activation forms such inhibits avoiding gatekeeper when simpler with is as FLTX JAKX FLTX proliferation emergence and or compromise pathways. in class inhibitor treatment the MAP a ERK while kinase including the mood JAKX lead of agent of with as kinase may factor inhibitors cKIT, resistance the ITD, resistance including with TKD rescue pathways SYK, inhibiting as as azacitidine. FLTX, competitors may than or safety. to conferring superior mutation, all of can mutant single just a that it that JAK/STAT inhibition important well wild-type validated forms particular of XXX resistance-conferring forms interfere pathways and mutant In as in other XXX inhibits as of targets signaling may and with and to from well pathways others it
IDHX in patients AML a kinase An active and or relapsed activity domain XXX As kinase ITD and in milligrams XXX model have FLTX of profile XXX an already includes diverse well-tolerated multiple to the I'll wild-type XXX we at remind the durable, refractory broad well Phase a harboring in this TPXX, with combinations highly FLTX. even trial have efficacy suggests milligrams tolerability. patients mutations antileukemic drugs can pre the XX into and adverse the reported, we remissions and as far. of already has as inhibitory the are thus with and other of of array paired array NPMX, -clinical with create have We disease. translated treating tyrosine you; complete patients strong, RAS, be co-mutations, at forms paired that delivering effective with more striking in animal with in shown X as extensive drug genes drug
to expansion ensure window, reduce no on asked efficacy about in dose XXX-milligram of we the cohort table. activity therapeutic leave to we the breadth risk sub-populations XXX exploring Now of characterize on the We're of different to often full patients. regulatory AML the and are an
two-thirds, to at multiple treat population. it to antileukemic since illustrate have as and frontline [Indiscernible] refractory patients, and observations well FLTX been the to appears Our dose so has of AML, AML mutant FLTX a diagnosed patients, wild-type today date unfit as patients and about third other doses well-tolerated as potential as compromising activity at both newly levels the the population, fit the well active relapsed XXX
exploration the types ongoing according drugs. In I patients FDA all for that in successfully guidelines, the crossing designed our be and dose "dotting used " Is it exploring In expect AML newer addition, extensive Ts we the expansion are combination to in with ops. trial, can we other in Phase of dose
inhibitors, patients, mentioned, on seeking only have received Rice [Indiscernible]. we're in -mutant not focus previously they current other validated even in patients FLTX active As if as already FLTX-mutant such is FLTX to XXX trial. our Dr. We
so patients. now seek So can we mutation treat profile a better we define to appropriate to susceptible XXX,
We are with deliver thorough XXX seeing. patients challenging clinical RUNXX. can with and responding that respond of subgroups XXX breadth XXX and will likely that seeking adverse AML CR list of abnormalities in mutations, of patients we're help patients we're our our We what This to appear as the AML gene, or mutation us to in of includes in likely to to thereby believe of this patient responding to in MLL a deliberate, those the are undercover patients encouraged capable phase responses are by who a harboring genotypes as revealed development. to the to XXX. highly-adverse less genetic approach of well guiding define CRs growing forward respond AML respond, the path recent next
take could and have discussed a already doses, in we call, that and dose As identified two we milligrams XX our well-tolerated active XXX milligrams, serve last as expansion to trials. go-forward into
details AML XXX and accelerated to further and explore over next genetically our pathways. dose we towards to dose defined collect our next of time, registrational we at expansion all few continue populations studies eye expansion plan patient [Indiscernible] milligram so it month. event optimal to XXX select dose the the data and continuing we providing date the corporate the initiate select data an Well, fixed disclose not with available may to this we're weeks at We patients levels to are
luxeptinib. quick a onto review of now, Okay,
activity BTK and potent associated observed tumor the BTK patient Pre the potently avoids agent patients. the far aggressive had activity engagement greater original the orally to target in consistently a a models well lux XXX the toxicities. at has clear and these report dependent exposure and in disease. only to did is formulation has even dose achieved of demonstrates levels BID antitumor exposure not FLTX lux drug level. multiple milligram absorbed in are animal demonstrated dose in that antitumor the that reminder, the targets patient, a inhibits with But including reductions -clinically, AML and of cancers. administered FLTX enough CR in Just known both we one that exposures less with achieve And for relapsed and drug clinical lux known precision Clinically, often treat effectively
As the made to formulation lux dosing clinical may evaluation and that After report level, of we've in last we new significant three the in XXX be two collected milligrams GX we original levels, patients to dose GX enable pleased across a different dose ongoing then the dose patients. for our our and able which our on at for which to the recently samples competing escalating with and greater I'm of direct exposures formulation we dosed comparison. mentioned call, GX have now received call at patients a patients GX program. progress PK go XX-milligram dose, single are lux to safely
date discuss PK our we As event. the upcoming call, and data mentioned them on our are at GX last in to to encouraging plan KOL corporate further
data ongoing We sufficiently profile. take can those single allow PK escalation. which studies PK formulation, dose the continuous the continuous to model to and data and FDA GX define to continue us transition If profile those to fully will request us with expect dosing we compelling, are modeling dose dose the plan the with single will the we to data, from to PK allow GX that dosing
greater delivering thereby substance addition drug the amount drug In to higher the drug and we exposures in and expect may trials. of manufactured substance GX responses, amounts potentially that the to product of to the pill burden, may significantly administered formulation the result patients, support reduce
drawing out me let recent three release lux. of highlighting the attention review to publications lux the by press close Finally,
insights lux -induced ability of at novel models. inflammatory along inflammation-induced by as effects provided makes One [Indiscernible] NLRPX of as inflammatory inflammasome which the to for luxeptinib in well well inflammation treatment toxicity pathways, autoimmune which candidate inflammatory those to tolerated protective autoimmune its signaling with of and the against inflammation, are in related endotoxin potential with in resistance interferes cancer. a into papers disease, patients The and clinical diseases, and was pathways concentrations associated it mechanisms inhibit the of
look We month. remain and clinical are We to regulatory providing very progress further you pleased discipline programs. XXX our to reduce to the our next in we steadfast risk in with lux updates and forward
For more clinical trials and please information visit that all ongoing our are recruiting clinical on patients, of sites clinicaltrials.gov.
you, financials. to Dr. it the turn I'll now, back Rice, review to For Will.
